News
![Roche Rituxan approval](https://pharmaphorum.com/wp-content/uploads/2016/05/Roche-sign.jpg)
Roche builds case for TIGIT combo in untreated lung cancer
Roche's closely-watched combination of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq has shown long-term efficacy in an ongoing trial in lung cancer, adding to the evidence